A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
A Note on Safety We built medicinal-use.com to help make sense of the UK’s changing laws, but we aren’t doctors. This content is for research and education—it isn’t medical advice. Before changing your healthcare routine or starting a new treatment, please speak with a GMC-registered clinician. Your safety matters more than any article we write.
This follow-up article builds on the initial overview of medical cannabis for migraine and cluster headaches. It dives deeper into patient-reported outcomes from 2025 UK registries, common product protocols used in private clinics, emerging patterns in efficacy, and additional safety/practical considerations for long-term use.
1. Deeper Look at 2026 Real-World Data
Recent updates from the UK Medical Cannabis Registry and private clinic cohorts (Releaf, Curaleaf, Mamedica) show:
- Migraine patients (chronic/refractory): 55–70% report reduction in monthly migraine days by ≥50% after 3–6 months (observational data). Many note decreased reliance on triptans and preventive meds.
- Cluster headache patients: Smaller cohort but higher response rate — ~65% report fewer attacks per week and less severe intensity. THC-dominant flower (vaporised) appears more effective for acute cluster attacks than oils for some.
- Patterns: Patients with comorbid anxiety or sleep issues often see greater overall benefit (secondary symptom relief). Those with purely hormonal migraine triggers report more variable results.
No new RCTs in 2025, but registry data continues to support private prescribing for treatment-resistant cases.
2. Typical Private Clinic Protocols (2026)
Clinics are refining approaches based on registry feedback:
- Preventive (daily): CBD-dominant or balanced low-THC oils/capsules (e.g., 10–30 mg CBD + 5–10 mg THC per dose). Taken consistently to reduce frequency.
- Acute (as-needed): THC-dominant flower or high-THC oils for breakthrough attacks (vaporised or sublingual for faster onset). Some clinics recommend suppositories for severe nausea.
- Titration: Start at 5–10 mg combined cannabinoids → increase weekly based on response. Most aim for lowest effective dose to minimize side effects.
- Monitoring: Monthly follow-ups first 3 months, then quarterly. Headache diaries (frequency, severity, triggers) required.
3. CBD vs THC – Updated Insights for Headache Disorders
| Aspect | CBD-Dominant (Preventive Focus) | THC-Inclusive (Acute Focus) |
|---|---|---|
| Primary Benefit | Reduced frequency/triggers (inflammation) | Acute attack relief (pain, nausea) |
| Onset | 30–90 min (oils/capsules) | 5–15 min (vaporised flower) |
| Duration | 4–8 hours | 2–4 hours |
| 2025 Registry Notes | 60% report preventive benefit | 70% report acute relief (cluster especially) |
| Common Doses | 20–60 mg CBD/day | 5–20 mg THC per attack |
Clinics report better results when combining preventive CBD with as-needed THC.
4. Additional Risks & Practical Tips (2026 Updates)
- Rebound headaches: Some patients report increased frequency if THC is overused (similar to medication-overuse headache with triptans).
- Tolerance: THC tolerance develops in 20–30% of long-term users — clinics recommend drug holidays or CBD-only periods.
- Comorbidities: Patients with anxiety/depression see better outcomes; those with migraine + aura report more variability.
- Driving: Same DVLA rules apply — avoid driving within impairment window (typically 4–24 hours post-THC).
Tips from clinics: Keep a headache diary, track triggers, start low, and combine with non-drug strategies (hydration, sleep hygiene).
5. Legal & Practical Notes (Recap)
- CBPMs are prescription-only (Schedule 2).
- Possession without prescription illegal (Class B).
- Driving: Impairment windows apply — check DVLA.
- No NHS funding for migraine/cluster — full private cost.
Sources
- UK Medical Cannabis Registry 2026 updates
- NICE guidelines on CBPMs
- GMC specialist prescribing rules
- Real-world studies on cannabinoids and headache disorders (2023–2026)
- Clinic protocols (Releaf, Alternaleaf, Curaleaf)